New Indication Alert: Daiichi Sankyo’s Enhertu® (Trastuzumab Deruxtecan) Approved To Treat NSCLC With HER2 (ERBB2) Mutations

Aug 23, 2023

Daiichi Sankyo announced that Enhertu® (trastuzumab deruxtecan) has been approved in Japan for a new indication: to treat unresectable advanced or recurrent non-small cell lung cancer (NSCLC) with HER2 (ERBB2) mutations that has progressed after chemotherapy.

On 12 July 2023, Enhertu® was approved in the US for a new indication (unresectable or metastatic HER2-low breast cancer).

Print Page Mail Article